Clin2
NCT05814432Possibly a fitRecruiting

High-dose antifungal for widespread Histoplasmosis in HIV

Disseminated Histoplasma Capsulatum InfectionAIDS and InfectionsImmunosuppressionFungal Infection

Part of Immune system & allergy, Infections clinical trials.

This Phase 3 trial tests whether a high-dose form of amphotericin B made in tiny fat particles (liposomal amphotericin B) is safer and more effective for treating widespread Histoplasmosis in adults with HIV. It may help people who have a serious, whole-body infection caused by Histoplasma.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
279 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You’re an adult and being treated at one of the study hospitals
  • You have HIV (antiretroviral treatment use can be ongoing or not)
  • You have confirmed widespread (disseminated) Histoplasmosis by lab testing (like cultures, microscopy, tissue testing, or urine antigen test)
  • If you have a brain/spinal infection, doctors think there’s an alternative explanation, not Histoplasmosis in the CNS
  • You’re not pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07261150Not yet recruiting· Phase 3
Testing better treatments for severe histoplasmosis

This trial tests different combinations of medicines for people hospitalized with a serious fungal infection called histoplasmosis. The goal is to find the most effective way to treat the infection and help patients recover faster.

Minneapolis, Minnesota
NCT06926569Not yet recruiting
High-dose antifungal plus HIV meds for fungal infection

This trial tests a single high dose of a potent antifungal medicine (liposomal amphotericin B) combined with a modern HIV treatment (B/F/TAF) for people with HIV who have a serious fungal infection called talaromycosis. The goal is to see if this short, powerful treatment works well and is safe.

NCT03945448Recruiting· Phase 2/Phase 3
Single-dose antifungal for people with HIV and positive cryptococcal blood test

This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.

Kampala
NCT06178627Enrolling by invitation· Phase 4
Amphotericin B for non-HIV cryptococcal meningitis

This trial tests the drug amphotericin B for people with cryptococcal meningitis who do not have HIV. The goal is to see if this treatment is safe and effective.

Shanghai, Shanghai Municipality
NCT06525389Not yet recruiting· Phase 3
Testing a new antifungal strategy for talaromycosis

This study tests whether a combination of two antifungal drugs works well for treating talaromycosis, a serious fungal infection common in people with HIV. The goal is to find a more convenient and effective treatment.

Durham, North Carolina
NCT07725874Not yet recruiting
Liposomal amphotericin B for mold infections after liver transplant

This trial tests the safety and effectiveness of a medicine called liposomal amphotericin B for treating serious mold infections in liver transplant recipients. It compares this medicine to another antifungal called voriconazole, and may help find the best way to treat these infections after a liver transplant.

Hear when a new Immunosuppression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.